179 related articles for article (PubMed ID: 15285840)
1. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates.
El Ela AA; Härtter S; Schmitt U; Hiemke C; Spahn-Langguth H; Langguth P
J Pharm Pharmacol; 2004 Aug; 56(8):967-75. PubMed ID: 15285840
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp).
Schmitt U; Abou El-Ela A; Guo LJ; Glavinas H; Krajcsi P; Baron JM; Tillmann C; Hiemke C; Langguth P; Härtter S
J Neural Transm (Vienna); 2006 Jul; 113(7):787-801. PubMed ID: 16252067
[TBL] [Abstract][Full Text] [Related]
3. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
[TBL] [Abstract][Full Text] [Related]
4. In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes.
Schmitt U; Kirschbaum KM; Poller B; Kusch-Poddar M; Drewe J; Hiemke C; Gutmann H
Pharmacol Biochem Behav; 2012 Aug; 102(2):312-20. PubMed ID: 22525746
[TBL] [Abstract][Full Text] [Related]
5. The influence of enaminones on the transport and oral bioavailability of P-glycoprotein substrate therapeutic agents.
Salama NN; Scott KR; Eddington ND
Int J Pharm; 2004 Apr; 273(1-2):135-47. PubMed ID: 15010138
[TBL] [Abstract][Full Text] [Related]
6. Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier.
Ejsing TB; Linnet K
Hum Psychopharmacol; 2005 Mar; 20(2):149-53. PubMed ID: 15624117
[TBL] [Abstract][Full Text] [Related]
7. Nasal delivery of P-gp substrates to the brain through the nose-brain pathway.
Shingaki T; Hidalgo IJ; Furubayashi T; Sakane T; Katsumi H; Yamamoto A; Yamashita S
Drug Metab Pharmacokinet; 2011 Jun; 26(3):248-55. PubMed ID: 21317541
[TBL] [Abstract][Full Text] [Related]
8. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
9. Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT?
Ofer M; Wolffram S; Koggel A; Spahn-Langguth H; Langguth P
Eur J Pharm Sci; 2005 Jun; 25(2-3):263-71. PubMed ID: 15911222
[TBL] [Abstract][Full Text] [Related]
10. A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay.
Balimane PV; Chong S
Int J Pharm; 2005 Sep; 301(1-2):80-8. PubMed ID: 16023314
[TBL] [Abstract][Full Text] [Related]
11. Polymethoxylated flavones and other phenolic derivates from citrus in their inhibitory effects on P-glycoprotein-mediated transport of talinolol in Caco-2 cells.
Mertens-Talcott SU; De Castro WV; Manthey JA; Derendorf H; Butterweck V
J Agric Food Chem; 2007 Apr; 55(7):2563-8. PubMed ID: 17348674
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of fruit extracts on P-glycoprotein-related efflux carriers: an in-vitro screening.
Deferme S; Van Gelder J; Augustijns P
J Pharm Pharmacol; 2002 Sep; 54(9):1213-9. PubMed ID: 12356275
[TBL] [Abstract][Full Text] [Related]
13. In vitro models for the blood-brain barrier.
Garberg P; Ball M; Borg N; Cecchelli R; Fenart L; Hurst RD; Lindmark T; Mabondzo A; Nilsson JE; Raub TJ; Stanimirovic D; Terasaki T; Oberg JO; Osterberg T
Toxicol In Vitro; 2005 Apr; 19(3):299-334. PubMed ID: 15713540
[TBL] [Abstract][Full Text] [Related]
14. Distribution interactions between perazine and antidepressant drugs. In vivo studies.
Wójcikowski J; Daniel WA
Pol J Pharmacol; 2000; 52(6):449-57. PubMed ID: 11334238
[TBL] [Abstract][Full Text] [Related]
15. Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats.
Konishi H; Sumi M; Shibata N; Takada K; Minouchi T; Yamaji A
J Pharm Pharmacol; 2004 Oct; 56(10):1259-66. PubMed ID: 15482640
[TBL] [Abstract][Full Text] [Related]
16. Metabolic drug interactions with newer antipsychotics: a comparative review.
Spina E; de Leon J
Basic Clin Pharmacol Toxicol; 2007 Jan; 100(1):4-22. PubMed ID: 17214606
[TBL] [Abstract][Full Text] [Related]
17. Modulating effect of polyethylene glycol on the intestinal transport and absorption of prednisolone, methylprednisolone and quinidine in rats by in-vitro and in-situ absorption studies.
Shen Q; Li W; Lin Y; Katsumi H; Okada N; Sakane T; Fujita T; Yamamoto A
J Pharm Pharmacol; 2008 Dec; 60(12):1633-41. PubMed ID: 19000368
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban.
Gnoth MJ; Buetehorn U; Muenster U; Schwarz T; Sandmann S
J Pharmacol Exp Ther; 2011 Jul; 338(1):372-80. PubMed ID: 21515813
[TBL] [Abstract][Full Text] [Related]
19. Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Wang EJ; Casciano CN; Clement RP; Johnson WW
Biochem Biophys Res Commun; 2001 Nov; 289(2):580-5. PubMed ID: 11716514
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein (Abcb1) is involved in absorptive drug transport in skin.
Ito K; Nguyen HT; Kato Y; Wakayama T; Kubo Y; Iseki S; Tsuji A
J Control Release; 2008 Nov; 131(3):198-204. PubMed ID: 18725258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
